調査レポートカテゴリー： Infiniti Research TechNavio, 世界, 医療/バイオ

Global Hepatitis Drugs Market 2015-2019

肝炎治療薬の世界市場：A型肝炎、B型肝炎、C型肝炎

◆タイトル：Global Hepatitis Drugs Market 2015-2019
◆商品コード：IRTNTR6912
◆調査・発行会社：Technavio (Infiniti Research Ltd.)
◆発行日：2015年12月9日
◆ページ数：118
◆資料形式：pdf / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD3,000 ⇒換算￥330,000見積依頼/購入/質問フォーム
Five UserUSD3,500 ⇒換算￥385,000見積依頼/購入/質問フォーム
Enterprise License（全社内共有可）USD4,500 ⇒換算￥495,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

 【資料の概要】

当調査レポートでは、肝炎治療薬の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、疾患概要、肝炎治療薬の世界市場規模及び予測、種類別分析、製品別分析、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業（ベンダー）分析などの情報をお届けいたします。

About hepatitis
Hepatitis is an inflammatory condition that occurs due to infection by hepatitis virus. It predominantly affects the liver and also causes damage to other body parts such as digestive system and brain. Apart from viral infections, hepatitis can also be caused by toxic substances, alcohol consumption, and autoimmune diseases. The viruses that cause hepatitis are of several types: A, B, C, D, E, and G. The most common type of hepatitis viruses are A, B, and C. Hepatitis viruses can cause either acute or chronic infections.

Technavio’s analysts forecast the global hepatitis drugs market to grow at a CAGR of 17.1% over the period 2014-2019.

[Covered in this report]
The report includes the present scenario and the growth prospects of the global hepatitis drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hepatitis.

Technavio’s report, Global Hepatitis Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as the segmentation. The report includes a discussion of the key vendors operating in this market.

[Key regions]
• Americas
• APAC
• EMEA

[Key vendors]
• F. Hoffmann-La Roche
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Vertex Pharmaceuticals

[Other prominent vendors]
• Abbvie
• Achillion Pharmaceuticals
• Bristol-Myers Squibb
• Dynavax Technologies
• Mitsubishi Tanabe Pharma

[Market Driver]
• Emergence of IFN-free therapies
• For a full, detailed list, view our report

[Market challenge]
• Side-effects of current therapy
• For a full, detailed list, view our report

[Market trend]
• Collaborations and M&A
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Product offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease
• Classification
• Mode of transmission
• Epidemiology
• Diagnosis
• Symptoms
• Treatment

PART 06: Key marketed drugs
• Hepatitis A
• Hepatitis B
• Hepatitis C

PART 07: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 08: Market segmentation by type
• Hepatitis A
• Hepatitis B
• Hepatitis C

PART 09: Market segmentation by MOA
• Virus-specific agents
• Non-specific agents

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape
• Competitive scenario
• Gilead Sciences
• Johnson & Johnson
• F. Hoffman-La Roche
• Merck
• GlaxoSmithKline
• Vertex Pharmaceuticals
• Novartis
• Other prominent vendors

PART 17: Key vendor analysis
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck
• Novartis
• Roche
• Vertex Pharmaceuticals

PART 18: Appendix
• List of abbreviations

PART 19: Explore Technavio

[List of Exhibits]

Exhibit 01: Mode of transmission and incubation period of different types of hepatitis
Exhibit 02: Risk factors for hepatitis A transmission
Exhibit 03: Risk factors for hepatitis B transmission
Exhibit 04: Risk factors for hepatitis C transmission
Exhibit 05: Worldwide endemicity of HAV infection
Exhibit 06: Endemicity pattern of HBV worldwide
Exhibit 07: Prevalence of HBV in APAC
Exhibit 08: Acute hepatitis B infection by age group 2005-2013
Exhibit 09: Prevalence of hepatitis B in US 2005-2013
Exhibit 10: Estimated HBV incidence rates in APAC countries 2004
Exhibit 11: Prevalence rates of hepatitis C across different regions 2012
Exhibit 12: Antibodies indicating different hepatitis types
Exhibit 13: Tests for viral proteins and generic materials
Exhibit 14: Screening tests for hepatitis B infection
Exhibit 15: Screening tests for hepatitis C infection
Exhibit 16: Types of hepatitis and symptoms
Exhibit 17: Recommended dosages and schedules for hepatitis A vaccines
Exhibit 18: Recommended dosages and schedules for hepatitis B vaccines
Exhibit 19: Combination vaccines for hepatitis A and/or hepatitis B
Exhibit 20: Hepatitis A: Key marketed vaccines
Exhibit 21: Hepatitis B: Key marketed drugs
Exhibit 22: Hepatitis C: Key marketed drugs
Exhibit 23: Global hepatitis drugs market 2014-2019 ($ billions)
Exhibit 24: Five forces analysis
Exhibit 25: Market segmentation by type
Exhibit 26: Global hepatitis A drugs market 2014-2019 ($ billions)
Exhibit 27: Global hepatitis B drugs market 2014-2019 ($ billions)
Exhibit 28: Global hepatitis C drugs market 2014-2019 ($ billions)
Exhibit 29: Snapshot of global hepatitis drugs market
Exhibit 30: Classification of global hepatitis drugs market by MOA
Exhibit 31: Global hepatitis drugs market by geographical segmentation 2014
Exhibit 32: List of key drivers
Exhibit 33: List of key challenges
Exhibit 34: Impact of drivers and challenges
Exhibit 35: List of key trends
Exhibit 36: Gilead: Pipeline candidates for hepatitis B
Exhibit 37: Gilead Sciences: Pipeline candidates for hepatitis C
Exhibit 38: Gilead Sciences: Key takeaways
Exhibit 39: Johnson & Johnson: Global YoY revenue of Incivo 2012-2014 ($ millions)
Exhibit 40: Johnson & Johnson: Global revenue of Olysio 2014 ($ millions)
Exhibit 41: Johnson & Johnson: Key takeaways
Exhibit 42: Roche: Pipeline candidates for hepatitis C
Exhibit 43: F. Hoffman-La Roche: Key takeaways
Exhibit 44: Merck: Global YoY revenue of Victrelis 2011-2013 ($ millions)
Exhibit 45: Merck: Pipeline candidates for hepatitis C
Exhibit 46: Merck: Key takeaways
Exhibit 47: GlaxoSmithKline: Pipeline candidates for hepatitis B
Exhibit 48: GlaxoSmithKline: Pipeline candidates for hepatitis C
Exhibit 49: GlaxoSmithKline: Key takeaways
Exhibit 50: Vertex Pharmaceuticals: Global YoY revenue of Incivek 2011-2013 ($ millions)
Exhibit 51: Vertex Pharmaceuticals: Pipeline candidates for hepatitis C
Exhibit 52: Vertex Pharmaceuticals: Key takeaways
Exhibit 53: Novartis: Key takeaways
Exhibit 54: Gilead Sciences: List of key drugs
Exhibit 55: GlaxoSmithKline: Segmentation by product 2014
Exhibit 56: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 57: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billions)
Exhibit 58: Johnson & Johnson: Business segmentation
Exhibit 59: Johnson & Johnson: Key products of medical devices segment
Exhibit 60: Johnson & Johnson: Medical devices segmentation by revenue 2014
Exhibit 61: Merck: Business segmentation
Exhibit 62: Merck: Geographical segmentation
Exhibit 63: Business segmentation by revenue
Exhibit 64: Novartis: Business segmentation
Exhibit 65: Novartis: Geographical segmentation
Exhibit 66: Novartis: Business segmentation by revenue
Exhibit 67: Roche: Business segments
Exhibit 68: Roche: Pharmaceuticals segmentation
Exhibit 69: Roche: Revenue comparison by business segment
Exhibit 70: Roche: Geographical segmentation
Exhibit 71: Vertex Pharmaceuticals: Product segmentation by revenue
Exhibit 72: Vertex Pharmaceuticals: Product segmentation by revenue 2013 and 2014 ($ millions)
Exhibit 73: Vertex Pharmaceuticals: Geographical segmentation



【掲載企業】

F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Vertex Pharmaceuticals, Abbvie, Achillion Pharmaceuticals, Bristol-Myers Squibb, Dynavax Technologies, Mitsubishi Tanabe Pharma

【資料のキーワード】

A型肝炎、B型肝炎、C型肝炎、肝炎治療薬、医薬品

【調査方法】

一次資料による調査（業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など）及び二次資料による調査（Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど）

★調査レポート[肝炎治療薬の世界市場：A型肝炎、B型肝炎、C型肝炎] (Global Hepatitis Drugs Market 2015-2019 / IRTNTR6912)販売に関する免責事項
[肝炎治療薬の世界市場：A型肝炎、B型肝炎、C型肝炎] (Global Hepatitis Drugs Market 2015-2019 / IRTNTR6912)についてEメールでお問い合わせ
◆関連調査資料◆
  • 世界のC型肝炎治療薬市場（2014-2018）
  • 世界の感染症治療薬市場：抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬
  • 世界のB型肝炎ワクチン市場（2014-2018）
  • 米国の感染症治療薬市場：抗菌薬、抗ウイルス薬、抗真菌薬、抗寄生虫薬
  • 米国の抗肥満薬市場
  • トラベルワクチン（海外渡航者ワクチン）の世界市場
  • 肝臓病治療の世界市場：非アルコール性脂肪性肝疾患、肝硬変、肝癌、肝炎
  • 世界の喘息治療市場：気管支拡張薬、ロイコトリエン拮抗薬、肥満細胞安定化薬、免疫抑制剤
  • 腎臓がん治療薬の世界市場2015-2019
  • 抗菌薬の世界市場2015-2019

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆